Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information on the Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - The report reviews Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) Overview 8 Therapeutics Development 9 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Stage of Development 9 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Therapy Area 10 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Indication 11 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Companies 14 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Products under Development by Universities/Institutes 16 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 24 AMO Pharma Limited 24 Angelini Group 25 Celon Pharma Sp. z o.o. 26 DiaMedica Inc. 27 HitGen LTD 28 Jeil Pharmaceutical Co., Ltd. 29 Mitsubishi Tanabe Pharma Corporation 30 Neurim Pharmaceuticals Ltd 31 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Drug Profiles 32 AP-001 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 CPL-202100 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 DM-199 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 DM-204 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Drug to Inhibit GSK3-Beta for Alzheimer's Disease - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 IB-AD - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 JGK-263 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 manzamine A - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Neu-120 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecule to Inhibit GSK-3 Beta for Menkes Disease and Tauopathies - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecule to Inhibit GSK3b for Type 2 Diabetes - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Small Molecules to Inhibit GSK-3 Beta for CNS Disorders - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecules to Inhibit GSK-3 Beta for Neurodegenerative Diseases - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Small Molecules to Inhibit GSK3 Beta for Type 2 Diabetes, Oncology and Alzheimer's Disease - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 tideglusib - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Dormant Projects 52 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Discontinued Products 54 Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Featured News & Press Releases 55 Oct 05, 2016: DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199 55 Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 55 Aug 10, 2016: AMO Pharma Initiates Phase 2 Clinical Trial in UK for AMO-02 for Treatment of Congenital and Juvenile Onset Myotonic Dystrophy 55 Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 56 Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia 56 Nov 04, 2015: DiaMedica Provides Corporate Update 57 Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference 58 Feb 02, 2015: DiaMedica to Expand Focus of DM199 Development into Acute Vascular Diseases 58 Nov 17, 2014: DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes 59 Aug 07, 2014: DiaMedica Publishes Manuscript Summarizing Preclinical Data on DM199 Treatment for Type 2 Diabetes 59 Jun 10, 2014: DiaMedica to Present Clinical Abstract on DM199 at the 74th Annual American Diabetes Association Conference 59 Feb 19, 2014: DiaMedica announces successful completion of Phase 1 program for DM199 60 Jan 09, 2014: DiaMedica Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of DM199 in Type 2 Diabetic Patients 60 Sep 30, 2013: DiaMedica Announces Successful Phase I/II Clinical Results in Type 2 Diabetic Patients 60 Aug 20, 2013: DiaMedica Announces Completion of Enrollment of Type 2 Diabetic Patients in the DM199 Single Ascending Dose Clinical Study 61 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 23 Pipeline by AMO Pharma Limited, H2 2016 24 Pipeline by Angelini Group, H2 2016 25 Pipeline by Celon Pharma Sp. z o.o., H2 2016 26 Pipeline by DiaMedica Inc., H2 2016 27 Pipeline by HitGen LTD, H2 2016 28 Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 29 Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 30 Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 31 Dormant Projects, H2 2016 52 Dormant Projects (Contd..1), H2 2016 53 Discontinued Products, H2 2016 54
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.